Verification evidence is still being completed.
PDF / print export
ExPLoRNA Therapeutics Sp. z o.o.
Warsaw, Poland
- Verified lead
- Jacek Jemielity
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- mRNA Cap-Analog Technology, AvantCap and ExploCap Platforms, and mRNA Therapeutic Licensing
- Review cycle
- 24 April 2026
- Full address
- ul. Zwirki i Wigury 93/2157, 02-089 Warsaw, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- ExPLoRNA Therapeutics official site naming Prof. Jacek Jemielity as CEO and Co-founder.
- Editorial note
- Warsaw University spin-out with named co-founder CEO, proprietary mRNA cap-analog platforms (AvantCap and ExploCap), and Gates Foundation-funded programs.
mRNA Cap-Analog Technology, AvantCap and ExploCap Platforms, and mRNA Therapeutic Licensing
University of Warsaw spin-out, Gates Foundation funding record, Public CEO disclosure
Warsaw University spin-out with named co-founder CEO, proprietary mRNA cap-analog platforms (AvantCap and ExploCap), and Gates Foundation-funded programs.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Warsaw University spin-out with named co-founder CEO, proprietary mRNA cap-analog platforms (AvantCap and ExploCap), and Gates Foundation-funded programs.
- Lead
- Jacek Jemielity (verified ↗)
- Address
- ul. Zwirki i Wigury 93/2157, 02-089 Warsaw, Poland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- mRNA chemistry R&D
- Capabilities
- mRNA Cap-Analog Chemistry · AvantCap and ExploCap Platforms · mRNA Therapeutic Licensing
- Founded
- 2020
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Jacek Jemielity
Chief Executive Officer and Co-Founder
Full addressul. Zwirki i Wigury 93/2157, 02-089 Warsaw, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
ALEO KRS directory listing ExPLoRNA Therapeutics at Zwirki i Wigury 93/2157 in Warsaw.
Open sourcemRNA chemistry R&D
Warsaw, Poland. mRNA Cap-Analog Technology, AvantCap and ExploCap Platforms, and mRNA Therapeutic Licensing. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products and EMA for future oversight
University of Warsaw spin-out, Gates Foundation funding record, Public CEO disclosure
mRNA Cap-Analog Technology, AvantCap and ExploCap Platforms, and mRNA Therapeutic Licensing
Warsaw University spin-out with named co-founder CEO, proprietary mRNA cap-analog platforms (AvantCap and ExploCap), and Gates Foundation-funded programs.
Editorial note
ExPLoRNA Therapeutics is a University of Warsaw spin-out with a named co-founder CEO, proprietary mRNA cap-analog chemistry, and documented Gates Foundation program funding.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
mRNA Cap-Analog Chemistry
AvantCap and ExploCap Platforms
mRNA Therapeutic Licensing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
mRNA cap-analog synthesis
Platform licensing operations
Gates Foundation programs
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is ExPLoRNA Therapeutics Sp. z o.o. located?
- ExPLoRNA Therapeutics Sp. z o.o. operates from ul. Zwirki i Wigury 93/2157, 02-089 Warsaw, Poland, Warsaw, Poland.
- Who runs ExPLoRNA Therapeutics Sp. z o.o.?
- ExPLoRNA Therapeutics Sp. z o.o. is led by Jacek Jemielity, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does ExPLoRNA Therapeutics Sp. z o.o. do?
- Warsaw University spin-out with named co-founder CEO, proprietary mRNA cap-analog platforms (AvantCap and ExploCap), and Gates Foundation-funded programs. Core capabilities: mRNA Cap-Analog Chemistry, AvantCap and ExploCap Platforms, mRNA Therapeutic Licensing.
Editorial context
Related technical briefs
Briefs that name Warsaw as a covered market or city.